Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

Recruitment of men to a multi-centre diabetes prevention trial: an evaluation of traditional and online promotional strategies.

Bracken K, Hague W, Keech A, Conway A, Handelsman DJ, Grossmann M, Jesudason D, Stuckey B, Yeap BB, Inder W, Allan C, McLachlan R, Robledo KP, Wittert G.

Trials. 2019 Jun 19;20(1):366. doi: 10.1186/s13063-019-3485-2.

2.

Shortening of telomere length by metabolic factors in diabetes: protective effects of fenofibrate.

Sutanto SSI, McLennan SV, Keech AC, Twigg SM.

J Cell Commun Signal. 2019 Jun 15. doi: 10.1007/s12079-019-00521-x. [Epub ahead of print]

PMID:
31203557
3.

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.

Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP; FOURIER Steering Committee and Investigators.

J Am Coll Cardiol. 2019 Jun 18;73(23):2961-2970. doi: 10.1016/j.jacc.2019.03.513.

PMID:
31196453
4.

Integrating diabetic retinopathy screening within diabetes education services in Australia's diabetes and indigenous primary care clinics.

Atkinson-Briggs S, Jenkins A, Keech A, Ryan C, Brazionis L; Centre of Research Excellence (CRE) in Diabetic Retinopathy.

Intern Med J. 2019 Jun;49(6):797-800. doi: 10.1111/imj.14309.

PMID:
31185524
5.

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.

Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, Jukema JW, Toth K, Tikkanen MJ, Im K, Wiviott SD, Kurtz CE, Honarpour N, Giugliano RP, Keech AC, Sever PS, Sabatine MS.

JAMA Cardiol. 2019 May 22. doi: 10.1001/jamacardio.2019.0886. [Epub ahead of print]

PMID:
31116355
6.

Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trial.

Bracken K, Keech A, Hague W, Kirby A, Robledo KP, Allan C, Conway A, Daniel M, Gebski V, Grossmann M, Handelsman DJ, Inder W, Jenkins A, McLachlan R, Stuckey B, Yeap BB, Wittert G.

J Clin Epidemiol. 2019 Apr 30;112:45-52. doi: 10.1016/j.jclinepi.2019.04.009. [Epub ahead of print]

PMID:
31051248
7.

Recruitment strategies in randomised controlled trials of men aged 50 years and older: a systematic review.

Bracken K, Askie L, Keech AC, Hague W, Wittert G.

BMJ Open. 2019 Apr 3;9(4):e025580. doi: 10.1136/bmjopen-2018-025580.

8.

The case for extended thromboprophylaxis in medically hospitalised patients - not yet made.

Cao JY, Lee SY, Dunkley S, Adams M, Keech A.

Eur J Prev Cardiol. 2019 Mar 16:2047487319836572. doi: 10.1177/2047487319836572. [Epub ahead of print]

PMID:
30880440
9.

Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein.

Yuan J, Tan JTM, Rajamani K, Solly EL, King EJ, Lecce L, Simpson PJL, Lam YT, Jenkins AJ, Bursill CA, Keech AC, Ng MKC.

Diabetes. 2019 May;68(5):1040-1053. doi: 10.2337/db17-0926. Epub 2019 Feb 14.

PMID:
30765336
10.

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.

O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS.

Circulation. 2019 Mar 19;139(12):1483-1492. doi: 10.1161/CIRCULATIONAHA.118.037184.

11.

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.

Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee and Investigators.

Circulation. 2019 Jan 15;139(3):366-375. doi: 10.1161/CIRCULATIONAHA.118.038341.

PMID:
30586726
12.

Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.

Qamar A, Giugliano RP, Keech AC, Kuder JF, Murphy SA, Kurtz CE, Wasserman SM, Sever PS, Pedersen TR, Sabatine MS.

JAMA Cardiol. 2019 Jan 1;4(1):59-63. doi: 10.1001/jamacardio.2018.4178.

PMID:
30540337
13.

Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trial.

Wittert G, Atlantis E, Allan C, Bracken K, Conway A, Daniel M, Gebski V, Grossmann M, Hague W, Handelsman DJ, Inder W, Jenkins A, Keech A, McLachlan R, Robledo K, Stuckey B, Yeap BB.

Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13601. [Epub ahead of print]

PMID:
30520208
14.

High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study).

Ong KL, Hui N, Januszewski AS, Kaakoush NO, Xu A, Fayyad R, DeMicco DA, Jenkins AJ, Keech AC, Waters DD, Barter PJ, Rye KA.

Metabolism. 2019 Apr;93:93-99. doi: 10.1016/j.metabol.2018.11.006. Epub 2018 Nov 16.

PMID:
30452928
15.

High-Intensity Interval Training for Patients With Cardiovascular Disease-Is It Safe? A Systematic Review.

Wewege MA, Ahn D, Yu J, Liou K, Keech A.

J Am Heart Assoc. 2018 Nov 6;7(21):e009305. doi: 10.1161/JAHA.118.009305.

16.

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.

Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee Investigators.

Lancet. 2018 Nov 24;392(10161):2269-2279. doi: 10.1016/S0140-6736(18)32328-6. Epub 2018 Oct 4.

17.

The princess and the p-value: A case report of suspected autoimmune encephalitis and functional neurological disorder in a pediatric patient.

Wilkinson-Smith A, Greenberg B, Keech A.

Appl Neuropsychol Child. 2018 Sep 28:1-8. doi: 10.1080/21622965.2018.1501373. [Epub ahead of print]

PMID:
30265565
18.

Attractions and barriers to Australian physician-researcher careers.

Mills JMZ, Januszewski AS, Robinson BG, Traill CL, Jenkins AJ, Keech AC.

Intern Med J. 2019 Feb;49(2):171-181. doi: 10.1111/imj.14086.

PMID:
30152020
19.

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM; CAMELLIA–TIMI 61 Steering Committee and Investigators.

N Engl J Med. 2018 Sep 20;379(12):1107-1117. doi: 10.1056/NEJMoa1808721. Epub 2018 Aug 26.

20.

Intensity-dependent effects of aerobic training on pressure pain threshold in overweight men: A randomized trial.

Hakansson S, Jones MD, Ristov M, Marcos L, Clark T, Ram A, Morey R, Franklin A, McCarthy C, Carli LD, Ward R, Keech A.

Eur J Pain. 2018 Nov;22(10):1813-1823. doi: 10.1002/ejp.1277. Epub 2018 Jul 11.

PMID:
29956398
21.

Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial.

Martin SS, Giugliano RP, Murphy SA, Wasserman SM, Stein EA, Ceška R, López-Miranda J, Georgiev B, Lorenzatti AJ, Tikkanen MJ, Sever PS, Keech AC, Pedersen TR, Sabatine MS.

JAMA Cardiol. 2018 Aug 1;3(8):749-753. doi: 10.1001/jamacardio.2018.1533.

22.

Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol.

McAuley SA, de Bock MI, Sundararajan V, Lee MH, Paldus B, Ambler GR, Bach LA, Burt MG, Cameron FJ, Clarke PM, Cohen ND, Colman PG, Davis EA, Fairchild JM, Hendrieckx C, Holmes-Walker DJ, Horsburgh JC, Jenkins AJ, Kaye J, Keech AC, King BR, Kumareswaran K, MacIsaac RJ, McCallum RW, Nicholas JA, Sims C, Speight J, Stranks SN, Trawley S, Ward GM, Vogrin S, Jones TW, O'Neal DN.

BMJ Open. 2018 Jun 9;8(6):e020274. doi: 10.1136/bmjopen-2017-020274.

23.

Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.

Bohula EA, Scirica BM, Fanola C, Inzucchi SE, Keech A, McGuire DK, Smith SR, Abrahamsen T, Francis BH, Miao W, Perdomo CA, Satlin A, Wiviott SD, Sabatine MS.

Am Heart J. 2018 Aug;202:39-48. doi: 10.1016/j.ahj.2018.03.012. Epub 2018 Mar 29.

PMID:
29803985
24.

Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy.

Harmer JA, Keech AC, Veillard AS, Skilton MR, Watts GF, Celermajer DS; FIELD Vascular Study Investigators.

Diabetes Res Clin Pract. 2018 Jul;141:156-167. doi: 10.1016/j.diabres.2018.05.006. Epub 2018 May 26.

PMID:
29763709
25.

Tear osmolarity changes after use of hydroxypropyl-guar-based lubricating eye drops.

Ng A, Keech A, Jones L.

Clin Ophthalmol. 2018 Apr 10;12:695-700. doi: 10.2147/OPTH.S150587. eCollection 2018.

26.

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease.

Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR.

Circulation. 2018 Aug 21;138(8):756-766. doi: 10.1161/CIRCULATIONAHA.118.034309.

27.

Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with type 1 diabetes is common.

Larsson CR, Januszewski AS, McGrath RT, Ludvigsson J, Keech AC, MacIsaac RJ, Ward GM, O'Neal DN, Fulcher GR, Jenkins AJ.

Intern Med J. 2018 Sep;48(9):1080-1086. doi: 10.1111/imj.13798.

PMID:
29573166
28.

Clinical benefits of evolocumab appear less than hoped - Authors' reply.

Giugliano RP, Keech AC, Sever PS, Pedersen TR, Sabatine MS.

Lancet. 2018 Mar 10;391(10124):934-935. doi: 10.1016/S0140-6736(18)30529-4. No abstract available.

29.

Inflammatory and Cholesterol Risk in the FOURIER Trial.

Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS.

Circulation. 2018 Jul 10;138(2):131-140. doi: 10.1161/CIRCULATIONAHA.118.034032. Epub 2018 Mar 12.

30.

Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.

Waldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L, Davis TME, Best JD, Li L, Feher MD, Foucher C, Kesaniemi YA, Flack J, d'Emden MC, Scott RS, Hedley J, Gebski V, Keech AC; FIELD investigators.

Lancet Diabetes Endocrinol. 2018 Apr;6(4):310-318. doi: 10.1016/S2213-8587(18)30029-9. Epub 2018 Feb 26.

PMID:
29496472
31.

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.

Koopal C, Visseren FLJ, Westerink J, van der Graaf Y, Ginsberg HN, Keech AC.

Diabetes Care. 2018 Jun;41(6):1244-1250. doi: 10.2337/dc17-0968. Epub 2018 Feb 22.

PMID:
29472432
32.

Diabetic retinopathy in a remote Indigenous primary healthcare population: a Central Australian diabetic retinopathy screening study in the Telehealth Eye and Associated Medical Services Network project.

Brazionis L, Jenkins A, Keech A, Ryan C, Brown A, Boffa J, Bursell S; CRE in Diabetic Retinopathy and the TEAMSnet Study Group.

Diabet Med. 2018 May;35(5):630-639. doi: 10.1111/dme.13596. Epub 2018 Feb 27.

PMID:
29405370
33.

D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease.

Simes J, Robledo KP, White HD, Espinoza D, Stewart RA, Sullivan DR, Zeller T, Hague W, Nestel PJ, Glasziou PP, Keech AC, Elliott J, Blankenberg S, Tonkin AM; LIPID Study Investigators.

Circulation. 2018 Aug 14;138(7):712-723. doi: 10.1161/CIRCULATIONAHA.117.029901.

PMID:
29367425
34.

Autonomic nervous system function, activity patterns, and sleep after physical or cognitive challenge in people with chronic fatigue syndrome.

Cvejic E, Sandler CX, Keech A, Barry BK, Lloyd AR, Vollmer-Conna U.

J Psychosom Res. 2017 Dec;103:91-94. doi: 10.1016/j.jpsychores.2017.10.010. Epub 2017 Oct 19.

PMID:
29167053
35.

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).

Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS.

Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13.

36.

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.

Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MS.

JAMA Cardiol. 2017 Dec 1;2(12):1385-1391. doi: 10.1001/jamacardio.2017.3944.

37.

Delayed versus Immediate Cord Clamping in Preterm Infants.

Tarnow-Mordi W, Morris J, Kirby A, Robledo K, Askie L, Brown R, Evans N, Finlayson S, Fogarty M, Gebski V, Ghadge A, Hague W, Isaacs D, Jeffery M, Keech A, Kluckow M, Popat H, Sebastian L, Aagaard K, Belfort M, Pammi M, Abdel-Latif M, Reynolds G, Ariff S, Sheikh L, Chen Y, Colditz P, Liley H, Pritchard M, de Luca D, de Waal K, Forder P, Duley L, El-Naggar W, Gill A, Newnham J, Simmer K, Groom K, Weston P, Gullam J, Patel H, Koh G, Lui K, Marlow N, Morris S, Sehgal A, Wallace E, Soll R, Young L, Sweet D, Walker S, Watkins A, Wright I, Osborn D, Simes J; Australian Placental Transfusion Study Collaborative Group.

N Engl J Med. 2017 Dec 21;377(25):2445-2455. doi: 10.1056/NEJMoa1711281. Epub 2017 Oct 29.

38.

Triglyceride-lowering trials.

Keech AC, Jenkins AJ.

Curr Opin Lipidol. 2017 Dec;28(6):477-487. doi: 10.1097/MOL.0000000000000465. Review.

PMID:
28957862
39.

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR.

Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15.

40.

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators.

Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28.

41.

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.

Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS.

JAMA Cardiol. 2017 Oct 1;2(10):1069-1078. doi: 10.1001/jamacardio.2017.2762. Erratum in: JAMA Cardiol. 2017 Oct 1;2(10):1170.

42.

Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study).

Sharman JE, Stanton T, Reid CM, Keech A, Roberts-Thomson P, Stewart S, Greenough R, Stowasser M, Abhayaratna WP.

Contemp Clin Trials. 2017 Nov;62:37-42. doi: 10.1016/j.cct.2017.08.010. Epub 2017 Aug 16.

PMID:
28822828
43.

Cognitive Function in a Randomized Trial of Evolocumab.

Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators.

N Engl J Med. 2017 Aug 17;377(7):633-643. doi: 10.1056/NEJMoa1701131.

44.

Reply to letter to the editor: high-intensity interval training vs. moderate-intensity continuous training: the lack of equalization, an ongoing problem.

Wewege MA, Ward RE, Keech A.

Obes Rev. 2017 Oct;18(10):1225-1226. doi: 10.1111/obr.12586. Epub 2017 Jul 20. No abstract available.

PMID:
28730659
45.

Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.

Ong KL, O'Connell R, Januszewski AS, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Waldman B, Colman PG, Best JD, Simes JR, Rye KA, Keech AC; FIELD study investigators.

Clin Chem. 2017 Jul;63(7):1261-1270. doi: 10.1373/clinchem.2016.270876. Epub 2017 Jun 12.

46.

Twelve-lead ambulatory electrocardiographic monitoring in Brugada syndrome: Potential diagnostic and prognostic implications.

Gray B, Kirby A, Kabunga P, Freedman SB, Yeates L, Kanthan A, Medi C, Keech A, Semsarian C, Sy RW.

Heart Rhythm. 2017 Jun;14(6):866-874. doi: 10.1016/j.hrthm.2017.02.026.

PMID:
28528724
47.

The effects of high-intensity interval training vs. moderate-intensity continuous training on body composition in overweight and obese adults: a systematic review and meta-analysis.

Wewege M, van den Berg R, Ward RE, Keech A.

Obes Rev. 2017 Jun;18(6):635-646. doi: 10.1111/obr.12532. Epub 2017 Apr 11. Review.

PMID:
28401638
48.

Reply: High Intensity Interval versus Moderate Intensity Continuous Training in Patients with Coronary Artery Disease.

Liou K, Keech A, Yu J, Fildes J, Ooi SY.

Heart Lung Circ. 2017 May;26(5):528-529. doi: 10.1016/j.hlc.2017.01.006. No abstract available.

PMID:
28377031
49.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

50.

Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.

Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators.

Clin Cardiol. 2017 Feb;40(2):59-65. doi: 10.1002/clc.22678. Epub 2017 Feb 16.

Supplemental Content

Support Center